Anixa Biosciences, Inc. (ANIX)

Anixa Biosciences Income Statement

Financials in millions USD. Fiscal year is November - October.

Year Ending	TTM	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021	Oct 31, 2020	Oct 31, 2019
Revenue	-	0.21	-	0.51	-	0.25
Revenue Growth (YoY)	-	-	-	-	-	-77.53%
Cost of Revenue	-	0.16	-	0.39	-	0.17
Gross Profit	-	0.05	-	0.13	-	0.08
Selling, General & Admin	7.27	6.29	7.17	7.07	5.93	5.66
Research & Development	5.7	4.77	6.7	6.19	4.38	5.47
Depreciation & Amortization	-	-	-	-	-	0.42
Operating Expenses	12.97	11.06	13.88	13.26	10.32	11.56
Operating Income	-12.97	-11.01	-13.88	-13.14	-10.32	-11.47
Interest & Investment Income	1.23	1.08	0.1	0	0.03	0.07
EBT Excluding Unusual Items	-11.74	-9.93	-13.77	-13.13	-10.28	-11.4
Gain (Loss) on Sale of Assets	-	-	-	0.01	-0.15	-
Asset Writedown	-	-	-	-	-	-0.42
Other Unusual Items	-	-	-	-	0.34	-
Pretax Income	-11.74	-9.93	-13.77	-13.13	-10.09	-11.82
Earnings From Continuing Operations	-11.74	-9.93	-13.77	-13.13	-10.09	-11.82
Minority Interest in Earnings	0.14	0.12	0.18	0.17	0.07	0.17
Net Income	-11.6	-9.81	-13.6	-12.95	-10.02	-11.65
Net Income to Common	-11.6	-9.81	-13.6	-12.95	-10.02	-11.65
Shares Outstanding (Basic)	31	31	30	29	22	20
Shares Outstanding (Diluted)	31	31	30	29	22	20
Shares Change (YoY)	1.92%	2.00%	6.28%	28.57%	12.33%	12.29%
EPS (Basic)	-0.37	-0.32	-0.45	-0.45	-0.45	-0.59
EPS (Diluted)	-0.37	-0.32	-0.45	-0.45	-0.45	-0.59
Free Cash Flow	-7.18	-6.21	-6.49	-4.94	-6.19	-4.92
Free Cash Flow Per Share	-0.23	-0.20	-0.21	-0.17	-0.28	-0.25
Gross Margin	-	23.33%	-	24.80%	-	33.50%
Operating Margin	-	-5243.33%	-	-2565.63%	-	-4588.50%
Free Cash Flow Margin	-	-2956.67%	-	-964.45%	-	-1966.75%
EBITDA	-	-	-	-13.1	-10.28	-11
D&A For EBITDA	-	-	-	0.04	0.04	0.47
EBIT	-12.97	-11.01	-13.88	-13.14	-10.32	-11.47

Source: S&P Capital IQ. Standard template.